Results 61 to 70 of about 1,168,324 (310)

Proceedings of the biosimilars workshop at the International Symposium on Oncology Pharmacy Practice 2019. [PDF]

, 2020
The International Society of Oncology Pharmacy Practitioners organized a workshop to create learning opportunities on biosimilars in pharmacy practice on 10 October 2019.
Chan, Alexandre, Ke, Yu, Tan, Chia Jie
core  

Toward Cultural Oncology: The Evolutionary Information Dynamics of Cancer [PDF]

, 2003
'Racial' disparities among cancers, particularly of the breast and prostate, are something of a mystery. For the US, in the face of slavery and its sequelae, centuries of interbreeding have greatly leavened genetic differences between 'Blacks' and ...
Wallace, Deborah, Wallace, Robert G., Wallace, Rodrick   +2 more
core   +2 more sources

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham, Jasibel Vasquez‐Gonzalez, Samantha M. Barnada, Salome Tchotorlishvili, Latese Jones, Ryan Maguire, Genevieve Lewis, Kinza Rizwan, Jenny Deng, Salma Koachar, Drithi Patel, Hailey Shankle, Tessa Mulders, Namra Ajmal, Charalambos Solomides, Emad S. Alnemri, Teresa F. Alnemri, Ayesha A. Shafi, Leonard G. Gomella, Wm Kevin Kelly, Steven B. McMahon, Matthew J. Schiewer   +21 more
wiley   +1 more source

Patient-centric trials for therapeutic development in precision oncology [PDF]

, 2015
An enhanced understanding of the molecular pathology of disease gained from genomic studies is facilitating the development of treatments that target discrete molecular subclasses of tumours.
A Hollebecque, A-M Tsimberidou, AD Barker, AL Tam, Andrew V. Biankin, AT Shaw, AV Biankin, B Zhang, C Le Tourneau, C Le Tourneau, C Lin, C Printz, CK Lee, CR Lindsay, D Cook, D Slamon, D Zardavas, DD Von Hoff, DE Gerber, DJ Sargent, DT Le, EA Eisenhauer, ED Green, ES Kim, F André, GD Demetri, GM Frampton, IR Watson, J Ledermann, J Lewin, J Verweij, JA Sosman, JY Douillard, L Chin, L Chin, L Seguin, LA Chantrill, LB Alexandrov, LJ Esserman, LJ Esserman, M Hay, M Maemondo, MG Kris, MR Stratton, MR Stratton, N Roper, N Waddell, NM Hylton, PA Jänne, PN Lara Jr, R Dienstmann, R Simon, RR Kalf, S Matsumoto, S Sleijfer, Simon J. Hollingsworth, SJ Dawson, SJ Mandrekar, Steven Piantadosi, TA Yap, TJ Hudson   +60 more
core   +1 more source

Biosimilars in oncology

ESMO Open, 2018
Biosimilars will soon become broadly available in the oncology field, raising important questions from both patients and healthcare providers. These questions need to be clarified upfront, in order to increase confidence in using these therapies. In this podcast, Teresa Amaral (Young Oncologist Committee member) talks to Josep Tabernero (ESMO President
openaire   +3 more sources

Characterizing the salivary RNA landscape to identify potential diagnostic, prognostic, and follow‐up biomarkers for breast cancer

Molecular Oncology, EarlyView.
This study explores salivary RNA for breast cancer (BC) diagnosis, prognosis, and follow‐up. High‐throughput RNA sequencing identified distinct salivary RNA signatures, including novel transcripts, that differentiate BC from healthy controls, characterize histological and molecular subtypes, and indicate lymph node involvement.
Nicholas Rajan, Irina Primac, Emre Etlioglu, Laurens Debruyne, Ann Janssen, Magy Sallam, Kevin Tabury, Roel Quintens, Wiebren Tjalma, Mohammed Abderrafi Benotmane   +9 more
wiley   +1 more source

DNA damage response proteins in canine cancer as potential research targets in comparative oncology [PDF]

, 2021
Beatriz Hernández‐Suárez, David A. Gillespie, Aleksandra Pawlak   +2 more
openalex   +1 more source

Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology

Molecular Oncology, EarlyView.
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts, Senada Koljenović, Elise Daems, Karolien De Wael, Marc Peeters, Léon C. van Kempen, Greetje Vanhoutte, Karen Zwaenepoel, Timon Vandamme   +8 more
wiley   +1 more source

Nutritional Support for a Child With Juvenile Myelomonocytic Leukaemia at Various Stages of Antineoplastic Therapy: A Clinical Case

Вопросы современной педиатрии, 2019
Background. Juvenile myelomonocytic leukaemia is a malignant disease with clonal impairment of haematopoiesis, characterized by excessive proliferation of monocytic and granulocytic sprout.
Mariam S. Shamsutdinova, Yulia A. Alymova, Andrey Yu. Vashura   +2 more
doaj   +1 more source

INTERFERONS IN ONCOLOGY

International Journal of Clinical Practice, 1997
SUMMARY The interferons are natural glycoproteins secreted in response to various stimuli, including viral infection. They have antiviral, antiproliferative and immunomodulatory effects on different target cell populations. Since recombinant human interferons have become available, they have been tested in a wide range of malignancies.
P J, Woll, R, Pettengell
openaire   +2 more sources